院内感染診断の世界市場：市場規模・シェア・動向分析 (検査別・感染症別・製品別・種類別・地域別)、セグメント別予測 (2025年～2030年)

院内感染診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の院内感染診断の市場規模は2030年までに47億4,000万米ドルに達する見込みです。

世界の院内感染診断市場は、2025年から2030年にかけて1.49％の健全なCAGRで成長すると予測されています。市場成長の要因としては、MRSAやC. difficileなどの薬剤耐性病原体の増加、高齢者人口の高齢化、正確で信頼性の高い結果を短納期で提供する先進技術製品の開発が挙げられます。

業界成長のもう一つの要因は、中・低所得国からのHAI診断薬の需要増加であり、HAI診断薬市場の需要をさらに押し上げています。医療従事者の意識の高まりや政府のイニシアティブの提案が、業界の成長をさらに後押ししています。しかし、先進国における院内感染の有病率の低下は、業界の成長を妨げる可能性が高いです。

院内感染 (HAI) 診断市場は、感染症の種類および検査の種類に基づいて分類されます。感染の種類別では、尿路感染（UTI）、血流感染（BSI）、手術部位感染（SSI）、肺炎、その他に区分されます。2015年現在、尿路感染症分野が最大のシェアを占めると推定される一方、肺炎HAI診断薬は2025年から2030年までの期間に最も高いCAGRで成長すると予測されています。HAI診断薬産業はさらに分子検査とその他の体外検査に区分されます。HAI診断産業は、さらに分子検査とその他のインビトロ検査に細分化されます。分子診断のシェアは低いですが、今後数年で有利な成長が見込まれます。

院内感染診断市場：分析概要

• 消耗品セグメントは2024年に最大の収益シェアを占め、予測期間中に最速のCAGR 1.55%で成長すると予測されます。
• 血液検査セグメントは2024年に最大の収益シェアを占め、予測期間中に1.55%のCAGRで最速の成長が見込まれます。
• 欧州が市場を独占し、2024年には34.57％の最大収益シェアを占めました。これは、高い疾病負担、インフラの利用可能性、医療支出の増加、急速な技術進歩、政府の積極的な取り組み、患者意識の高まり、主要企業の存在によるものです。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 院内感染診断市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 浸透と成長の見込みマッピング
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
  • 市場機会
  • 市場の課題
• 院内感染診断市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 院内感染の診断：検査別の推定・動向分析

• 院内感染診断市場：重要なポイント
• 院内感染診断市場：動向と市場シェア分析 (2022年・2030年)
• 従来型
  • 従来の市場推計・予測、2018年から2030年
• 分子
  • 分子の市場推計・予測、2018年から2030年

第5章 院内感染の診断：感染症別の推定・動向分析

• 院内感染診断市場：重要なポイント
• 院内感染診断市場：動向と市場シェア分析 (2022年・2030年)
• 尿路感染症 (UTI)
  • UTIの市場推計・予測、2018年から2030年
• 肺炎
  • 肺炎の市場推計・予測、2018年から2030年
• 手術部位感染
  • 手術部位感染の市場推計・予測、2018年から2030年
• 血流感染症
  • 血流感染症の市場推計・予測、2018年から2030年
• その他
  • その他の感染症の市場推計・予測、2018年から2030年

第6章 院内感染診断：製品別の推定・動向分析

• 院内感染診断市場：重要なポイント
• 院内感染診断市場：動向と市場シェア分析 (2022年・2030年)
• 消耗品
  • 消耗品の市場推計・予測、2018年から2030年
• 装置
  • 装置の市場推計・予測、2018年から2030年

第7章 院内感染診断市場：種類別の推定・動向分析

• 院内感染診断市場：重要なポイント
• 種類別の展望
• 血液検査
• 尿検査

第8章 院内感染診断市場：地域別の推定・動向分析

• 地域別の展望
• 院内感染症診断市場：重要なポイント、地域別
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 最新動向と影響分析：主な市場参入企業別
• 企業/競合の分類
• 企業市場シェア分析 (2024年)
• 企業プロファイル
  • BIOMERIEUX
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare Private Limited
  • BD（Becton, Dickinson and Company）
  • Hologic, Inc.
  • Meridian Bioscience, Inc
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Bioscience, Inc.

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 3 North America hospital acquired infections diagnostics market, by infection Type, 2018 - 2030 (USD Million)
• Table 4 North America hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 5 North America hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 6 North America hospital acquired infections diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 7 U.S. hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 8 U.S. hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 9 U.S. hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 10 U.S. hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 11 Canada hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 12 Canada hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 13 Canada hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 14 Canada hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 15 Mexico hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 16 Mexico hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 17 Mexico hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 18 Mexico hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 19 Europe hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 20 Europe hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 21 Europe hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 22 Europe hospital acquired infections diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 23 UK hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 24 UK hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 25 UK hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 26 UK hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 27 Germany hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 28 Germany hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 29 Germany hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 30 Germany hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 31 France hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 32 France hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 33 France hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 34 France hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 35 Italy hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 36 Italy hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 37 Italy hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 38 Italy hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 39 Spain hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 40 Spain hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 41 Spain hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 42 Spain hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 43 Denmark hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 44 Denmark hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 45 Denmark hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 46 Denmark hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 47 Sweden hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 48 Sweden hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 49 Sweden hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 50 Sweden hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 51 Norway hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 52 Norway hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 53 Norway hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 54 Norway hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific hospital acquired infections diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 60 Japan hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 61 Japan hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 62 Japan hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 63 Japan hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 64 China hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 65 China hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 66 China hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 67 China hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 68 India hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 69 India hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 70 India hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 71 India hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 72 Australia hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 73 Australia hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 74 Australia hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 75 Australia hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 76 Thailand hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 77 Thailand hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 78 Thailand hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 79 Thailand hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 80 South Korea hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 81 South Korea hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 82 South Korea hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 83 South Korea hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 84 Latin America hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 85 Latin America hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 86 Latin America hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 87 Latin America hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 88 Latin America hospital acquired infections diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 89 Brazil hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 90 Brazil hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 91 Brazil hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 92 Brazil hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 93 Argentina hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 94 Argentina hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 95 Argentina hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 96 Argentina hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 97 Middle East and Africa hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 98 Middle East and Africa hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 99 Middle East and Africa hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 100 Middle East and Africa hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 101 Middle East and Africa hospital acquired infections diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 102 South Africa hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 103 South Africa hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 104 South Africa hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 105 South Africa hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 106 Saudi Arabia hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 110 UAE hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 111 UAE hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 112 UAE hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 113 UAE hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)
• Table 114 Kuwait hospital acquired infections diagnostics market, by test, 2018 - 2030 (USD Million)
• Table 115 Kuwait hospital acquired infections diagnostics market, by infection, 2018 - 2030 (USD Million)
• Table 116 Kuwait hospital acquired infections diagnostics market, by product, 2018 - 2030 (USD Million)
• Table 117 Kuwait hospital acquired infections diagnostics market, by type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 QFD modeling for market share assessment
• Fig. 6 Market formulation & validation
• Fig. 7 Microneedle Instruments systems: market outlook
• Fig. 8 Hospital Acquired Infections Diagnostics competitive insights
• Fig. 9 Parent market outlook
• Fig. 10 Related/ancillary market outlook
• Fig. 11 Penetration and growth prospect mapping
• Fig. 12 Hospital acquired infections diagnostics market driver impact
• Fig. 13 Hospital acquired infections diagnostics market restraint impact
• Fig. 14 Hospital acquired infections diagnostics market strategic initiatives analysis
• Fig. 15 Hospital acquired infections diagnostics market: Test type movement analysis
• Fig. 16 Hospital acquired infections diagnostics market: Test type outlook and key takeaways
• Fig. 17 Molecular market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Conventional market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Hospital acquired infections diagnostics market: Infection type movement analysis
• Fig. 20 Hospital acquired infections diagnostics market: Infection type outlook and key takeaways
• Fig. 21 UTI market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Pneumonia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Surgical site infection market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Blood stream infections market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Hospital acquired infections diagnostics market: Product movement analysis
• Fig. 27 Hospital acquired infections diagnostics market: Product outlook and key takeaways
• Fig. 28 Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 2030 Hospital Acquired Infections Diagnostics market: Type outlook and key takeaways
• Fig. 31 Blood tests market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Urinalysis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Global hospital acquired infections diagnostics market: Regional movement analysis
• Fig. 35 Global hospital acquired infections diagnostics market: Regional outlook and key takeaways
• Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Hospital Acquired Infections Diagnostics Market Growth & Trends:

The global hospital acquired infections diagnostics market size is expected to reach USD 4.74 billion by 2030, according to a new report by Grand View Research, Inc. The global hospital acquired infections diagnostics market is projected to grow at a healthy CAGR of 1.49% during the period of 2025 to 2030. Factors attributing to the growth of the market are increase in the number of drug-resistant pathogens such as MRSA and C. difficile, advancing age of geriatric population, and development of technologically advanced products that offer accurate and reliable results with low turnaround time.

Another factor contributing to industry growth is the increasing demand of HAI diagnostics from middle and low income countries, further driving demand for HAI diagnostic market. Increasing awareness among healthcare workers and proposed government initiatives are further supporting industry growth. However, decline in the prevalence rate of nosocomial infections in the developed countries is likely to hinder industry growth.

The HAI diagnostics market is categorized on the basis of infection type and test type. On the basis of infection type, the market is segmented into Urinary Tract Infection (UTI), Blood Stream Infection (BSI), Surgical Site Infection (SSI), pneumonia, and others. As of 2015, the urinary tract infection segment was estimated to account for the largest share, whereas the pneumonia HAI diagnostics is projected to grow at the highest CAGR during the period of 2025 to 2030.The HAI diagnostics industry is further segmented into molecular tests and other in-vitro tests. Though the molecular diagnostics segment is estimated to constitute a low share, it is anticipated to witness a lucrative growth in the next few years.

Hospital Acquired Infections Diagnostics Market Report Highlights:

• The consumables segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR of 1.55% over the forecast period,
• The blood tests segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR of 1.55% during the forecast period
• Europe dominated the market and accounted for the largest revenue share of 34.57% in 2024, owing to the high disease burden, the availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and the presence of major players.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Test
  • 1.1.2. Infection
  • 1.1.3. Product
  • 1.1.4. Type
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test outlook
  • 2.2.2. Infection outlook
  • 2.2.3. Product outlook
  • 2.2.4. Type outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Hospitals Acquired Infections Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Hospitals Acquired Infections Diagnostics Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Hospitals Acquired Infections Diagnostics: Test Estimates & Trend Analysis

• 4.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
• 4.2. Hospital Acquired Infections Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Conventional
  • 4.3.1. Conventional market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Molecular
  • 4.4.1. Molecular market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Hospital Acquired Infections Diagnostics: Infection Estimates & Trend Analysis

• 5.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
• 5.2. Hospital Acquired Infections Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. UTI
  • 5.3.1. UTI market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Pneumonia
  • 5.4.1. Pneumonia market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Surgical Site Infection
  • 5.5.1. Surgical site infection market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Blood Stream Infections
  • 5.6.1. Blood stream infections market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others infections market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Hospital Acquired Infections Diagnostics: Product Estimates & Trend Analysis

• 6.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
• 6.2. Hospital Acquired Infections Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Consumables
  • 6.3.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Instruments
  • 6.4.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Hospital Acquired Infections Diagnostics Market: Type Estimates & Trend Analysis

• 7.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
• 7.2. Type Outlook
  • 7.2.1. Type Outlook market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.3. Blood Tests
  • 7.3.1. Blood tests market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.4. Urinalysis
  • 7.4.1. Urinalysis market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Hospital Acquired Infections Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Outlook
• 8.2. Hospitals Acquired Infections Diagnostics Market by Region: Key Takeaways
• 8.3. North America
  • 8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key Country Dynamics
    • 8.4.1.2. Competitive Scenario
    • 8.4.1.3. Regulatory Framework
    • 8.4.1.4. Reimbursement Scenario
    • 8.4.1.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.4.6. Denmark
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.4.8. Norway
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Reimbursement Scenario
    • 8.4.8.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key Country Dynamics
    • 8.5.1.2. Competitive Scenario
    • 8.5.1.3. Regulatory Framework
    • 8.5.1.4. Reimbursement Scenario
    • 8.5.1.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Scenario
    • 8.5.4.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Scenario
    • 8.5.5.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Scenario
    • 8.5.6.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key Country Dynamics
    • 8.6.1.2. Competitive Scenario
    • 8.6.1.3. Regulatory Framework
    • 8.6.1.4. Reimbursement Scenario
    • 8.6.1.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key Country Dynamics
    • 8.7.1.2. Competitive Scenario
    • 8.7.1.3. Regulatory Framework
    • 8.7.1.4. Reimbursement Scenario
    • 8.7.1.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Scenario
    • 8.7.2.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Scenario
    • 8.7.3.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Reimbursement Scenario
    • 8.7.4.5. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Company Market Share Analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. BIOMERIEUX
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Abbott
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. F. Hoffmann-La Roche Ltd
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Siemens Healthcare Private Limited
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. BD (Becton, Dickinson and Company)
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Hologic, Inc.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Meridian Bioscience, Inc
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. QIAGEN
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Thermo Fisher Scientific Inc.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Bioscience, Inc.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives